Purdue University also made an announcement yesterday
“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” Aridor said. “Our solution will be both generic and personal”
It sounds fantastical, especially considering that an estimated 18.1 million new cancer cases are diagnosed worldwide each year, according to reports by the International Agency for Research on Cancer. Further, every sixth death in the world is due to cancer, making it the second leading cause of death (second only to cardiovascular disease).
Aridor, chairman of the board of AEBi and CEO Dr. Ilan Morad, say their treatment, which they call MuTaTo (multi-target toxin) is essentially on the scale of a cancer antibiotic – a disruption technology of the highest order.
The potentially game-changing anti-cancer drug is based on SoAP technology, which belongs to the phage display group of technologies. It involves the introduction of DNA coding for a protein, such as an antibody, into a bacteriophage – a virus that infects bacteria. That protein is then displayed on the surface of the phage. Researchers can use these protein-displaying phages to screen for interactions with other proteins, DNA sequences and small molecules.
( please see full article for the full story )
Forget curing all cancers. If they can find a cure for or greatly extend lives of people with AML, that would be a huge step forward. The problem with AML is in most cases AML is a secondary cancer, meaning it’s the result of chemotherapy treatment from a previous unrelated cancer. How many people know cancer treatment (chemo) itself can cause cancer ? Cancer from cancer treatment is one of the worst kinds called Acute Myeloid Leukemia (AML) with a 5 yr survival of only 30%. So I hope this Purdue study is a big step forward.